

## Futuximab

|                  |   |
|------------------|---|
| <b>Cat. No.:</b> | HY-P99628   |
| <b>CAS No.:</b>  | 1310460-85-5  |
| <b>Target:</b>   | EGFR  |
| <b>Pathway:</b>  | JAK/STAT Signaling; Protein Tyrosine Kinase/RTK   |
| <b>Storage:</b>  | Please store the product under the recommended conditions in the Certificate of Analysis. |

### BIOLOGICAL ACTIVITY

|                    |   |  |               |  |                |          |                  |                                 |         |  |
|--------------------|---|--|---------------|--|----------------|----------|------------------|---------------------------------|---------|--|
| <b>Description</b> | Futuximab is a chimeric monoclonal antibody targeting non-overlapping epitopes on EGFR. Futuximab has antineoplastic activity <sup>[1]</sup> .  |  |               |  |                |          |                  |                                 |         |  |
| <b>In Vitro</b>    | <p>Futuximab (20 µg/mL; 24-48 h) induces EGFR variant III (EGFRvIII) internalization and slightly reduces EGFRvIII levels in NR6M cells<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Western Blot Analysis<sup>[1]</sup></p> <table border="1"> <tr> <td>Cell Line:</td> <td>NR6M cells</td> </tr> <tr> <td>Concentration:</td> <td>20 µg/mL</td> </tr> <tr> <td>Incubation Time:</td> <td>24 h or 48 h</td> </tr> <tr> <td>Result:</td> <td>Slightly reduced EGFRvIII levels in NR6M cells.</td> </tr> </table>  |  | Cell Line:    | NR6M cells   | Concentration: | 20 µg/mL | Incubation Time: | 24 h or 48 h                    | Result: | Slightly reduced EGFRvIII levels in NR6M cells.              |
| Cell Line:         | NR6M cells  |  |               |  |                |          |                  |                                 |         |  |
| Concentration:     | 20 µg/mL  |  |               |  |                |          |                  |                                 |         |  |
| Incubation Time:   | 24 h or 48 h  |  |               |  |                |          |                  |                                 |         |  |
| Result:            | Slightly reduced EGFRvIII levels in NR6M cells.   |  |               |  |                |          |                  |                                 |         |  |
| <b>In Vivo</b>     | <p>Futuximab (50 mg/kg; i.p.; twice weekly; for 5 weeks) shows anti-tumor activity in EGFRwt expressing xenograft model<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Balb/c nu/nu mice injected with EGFRwt (D08-0308MG) patient-derived glioblastoma xenografts (PDX)<sup>[1]</sup></td> </tr> <tr> <td>Dosage:</td> <td>50 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>i.p.; twice weekly; for 5 weeks</td> </tr> <tr> <td>Result:</td> <td>Inhibited tumor growth in EGFRwt expressing xenograft model.</td> </tr> </table> |  | Animal Model: | Balb/c nu/nu mice injected with EGFRwt (D08-0308MG) patient-derived glioblastoma xenografts (PDX) <sup>[1]</sup> | Dosage:        | 50 mg/kg | Administration:  | i.p.; twice weekly; for 5 weeks | Result: | Inhibited tumor growth in EGFRwt expressing xenograft model. |
| Animal Model:      | Balb/c nu/nu mice injected with EGFRwt (D08-0308MG) patient-derived glioblastoma xenografts (PDX) <sup>[1]</sup>  |  |               |  |                |          |                  |                                 |         |  |
| Dosage:            | 50 mg/kg  |  |               |  |                |          |                  |                                 |         |  |
| Administration:    | i.p.; twice weekly; for 5 weeks   |  |               |  |                |          |                  |                                 |         |  |
| Result:            | Inhibited tumor growth in EGFRwt expressing xenograft model.  |  |               |  |                |          |                  |                                 |         |  |

### REFERENCES

[1]. Stephen T Keir, et al. Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models. J Neurooncol. 2018 Jul;138(3):489-498.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA